Luteolin

1. What conditions has Luteolin been studied for?

• Inflammation and inflammation-associated diseases: Multiple reviews describe luteolin as having “strong anti-inflammatory activity in vitro and in vivo,” with ethnopharmacologic use of luteolin-rich plants for inflammation-related symptoms.

• Neurodegenerative disorders: Especially Alzheimer’s disease (AD) (including a study in triple transgenic AD mice), and broader neurodegenerative conditions discussed in reviews (e.g., Parkinson’s disease, multiple sclerosis).

• Neurotrauma / traumatic brain injury (TBI) and related neuroinflammation: A review summarizes luteolin’s potential neuroprotective effects in TBI and stroke pathogenesis via anti-inflammatory/antioxidant mechanisms.

• Cancer: Multiple reviews summarize extensive preclinical research across “many cancer types,” including effects on tumor growth, apoptosis, angiogenesis, migration, and cell cycle.

• Metabolic and cardiovascular-related areas: Reviews mention potential roles in diabetes control and anti-cardiovascular effects (generally as areas of investigation/potential).

• Oxidative stress–related neuronal injury: Cell studies include glutamate-induced hippocampal neuronal cell death (HT-22 cells), where luteolin reduced ROS and apoptosis.

• COVID-19-related systemic/neuroinflammation: A short review notes reports suggesting luteolin suppresses systemic and neuroinflammatory responses in COVID-19 (as summarized by the review, not detailed as primary trial evidence in these studies).

2. Does it work in treating those conditions? Summarize the evidence.

• Anti-inflammatory effects: Supported mainly by preclinical evidence; limited clinical evidence.

  • One review (covering studies since 2009) states luteolin shows “strong anti-inflammatory activity in vitro and in vivo,” with major molecular targets including Src/NF-κB, MAPK/AP-1, and SOCS3/STAT3.

  • The same review mentions a clinical trial of a formulation containing luteolin with “excellent therapeutic effect against inflammation-associated diseases,” but the study does not provide trial design details, dose, endpoints, or whether luteolin was isolated vs. part of a multi-ingredient product—so the strength of clinical inference is limited.

• Alzheimer’s disease: Promising animal and cell evidence; not established in humans from these studies.

  • In 3×Tg-AD mice, luteolin supplementation “significantly ameliorated memory and cognitive impairment,” reduced neuronal apoptosis, inhibited Aβ generation, and repaired mitochondrial damage.

  • Mechanistically, luteolin was reported to directly bind PPARγ and promote its expression/function; blocking or knocking down PPARγ (GW9662 or siRNA) eliminated luteolin’s protective effects in primary neurons—supporting a PPARγ-dependent mechanism in that model.

  • These are strong mechanistic preclinical findings, but they do not demonstrate efficacy in human AD.

• Neuroprotection in injury/neuroinflammation: Suggestive preclinical/review-level support.

  • A review summarizes that luteolin can suppress activation of immune cells (including mast cells), reduce microglia/astrocyte activation, oxidative stress, and neuroinflammation, and may improve cognitive decline in neurodegenerative diseases, TBI, and stroke.

  • Cell evidence: In glutamate-injured HT-22 hippocampal cells, luteolin attenuated reduced viability, ROS increase, and apoptosis (pre-treatment model).

  • Overall, these data support biological plausibility and preclinical benefit, but do not establish clinical effectiveness.

• Cancer: Extensive preclinical evidence; clinical efficacy not established in these studies.

  • Reviews describe luteolin’s anticancer activity across cancer types via effects on apoptosis, angiogenesis, migration, and cell cycle progression, and via multiple signaling pathways.

  • Another review notes registered clinical trials are ongoing, but indicates clinical research on anticancer effects “should be continuously promoted,” implying current human evidence is limited/insufficient.

  • Combination therapy and nanodelivery strategies are discussed as approaches to improve efficacy and delivery, reflecting that translation challenges remain.

• Diabetes/cardiovascular: Mentioned as potential areas; efficacy not demonstrated in these studies.

  • Several reviews list antidiabetic and anti-cardiovascular properties as potential/observed pharmacological activities, but the studies reviewed here do not include specific trial outcomes or model results for these endpoints.

3. What health benefits does it have?

• Anti-inflammatory / immunomodulatory activity

  • Across reviews, luteolin is repeatedly characterized as a strong anti-inflammatory flavonoid, modulating key inflammatory signaling pathways including NF-κB, MAPKs, JAK/STAT (including STAT3), and inflammasome-related processes.

• Neuroprotective effects

  • In AD-model mice, luteolin improved cognition and reduced AD-like pathology (Aβ generation, mitochondrial dysfunction, neuronal apoptosis) via a PPARγ-dependent mechanism.

  • In neuronal cell models, luteolin reduced oxidative stress (ROS) and apoptosis in glutamate-induced injury.

  • Reviews suggest broader neuroprotective potential in neuroinflammation-driven conditions (e.g., TBI and neurodegenerative diseases) through suppression of glial activation and inflammatory mediators.

• Antioxidant effects

  • Multiple studies describe luteolin as having antioxidant activity, including reducing oxidative stress in neuronal models and being part of the broader flavonoid class with anti-oxidative effects.

• Anticancer potential (preclinical)

  • Reviews describe inhibition of tumor-related processes (proliferation, invasion, angiogenesis) and induction of apoptosis, cell-cycle arrest, autophagy modulation, and other regulated cell-death pathways (e.g., ferroptosis/pyroptosis mentioned in one review).

• Formulation/biopharmaceutic innovation potential

  • Several reviews note efforts to improve solubility and bioavailability (e.g., nanoparticles, liposomes, nanoemulsions, host-guest complexes), which is a “benefit” mainly in the sense of improving feasibility as a therapeutic agent.

4. Does it have any downsides or side effects?

• Limited safety detail in these studies

  • The anti-inflammatory review explicitly notes that “much work remains to ensure the safety, quality, and efficacy of luteolin before it can be used” for human inflammation-related diseases—indicating incomplete safety characterization.

  • A separate review states luteolin’s “safety profile” is discussed, but the study does not provide specific adverse events, rates, or contraindications.

• Low oral bioavailability and extensive metabolism (practical downside)

  • One anticancer-focused review states luteolin has “unfavorable oral bioavailability” and persists in plasma mainly as glucuronide and sulfate conjugates after metabolism—potentially limiting predictable systemic exposure to the parent compound.

• Potential drug–nutrient/drug–drug interaction risk via transporters

  • The same review describes luteolin as a “potent inhibitor” of OATP1B1 and OATP2B1, raising the possibility of pharmacokinetic interactions with other substances that rely on these uptake transporters (the study does not quantify clinical magnitude, but flags a plausible risk).

• Evidence limitations

  • Much of the supportive evidence in these studies is from in vitro and animal models; benefits and risks in humans may differ due to dosing, metabolism, and disease complexity.

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The studies reviewed here do not report specific pharmacogenomic findings (e.g., genotype-stratified responses, variant-specific efficacy/toxicity) for luteolin.

• Mechanistic hints but no genotype data: The AD mouse/cell study identifies a PPARγ-dependent mechanism (luteolin binding and functional upregulation of PPARγ), but it does not evaluate whether human PPARG genetic variants alter response.

• Transporter interaction relevance: The anticancer pharmacokinetics review flags inhibition of OATP1B1/OATP2B1. In principle, genetic variants in transporter genes (e.g., SLCO1B1 for OATP1B1) could modify interaction risk, but the studies do not provide direct evidence.

• Bottom line: Based on these studies alone, there is insufficient evidence to claim luteolin is beneficial or harmful for particular genetic subgroups; this remains an evidence gap.

References

1. Luteolin: A promising multifunctional natural flavonoid for human diseases.
   Mingtao Zhu, Yanping Sun, Yang Su, Wei Guan, Yu Wang, Jianwei Han, Shuang Wang, Bingyou Yang, Qiuhong Wang, Haixue Kuang (2024) - Phytotherapy research : PTR
2. Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies.
   Nur Aziz, Mi-Yeon Kim, Jae Youl Cho (2018) - Journal of ethnopharmacology
3. Protective effects of luteolin against amyloid beta-induced oxidative stress and mitochondrial impairments through peroxisome proliferator-activated receptor γ-dependent mechanism in Alzheimer's disease.
   Zhijun He, Xiaoqian Li, Zi Wang, Yingqi Cao, Shuangxue Han, Nan Li, Jie Cai, Shuiyuan Cheng, Qiong Liu (2023) - Redox biology
4. Therapeutic Potential of Luteolin on Cancer.
   Melisa Çetinkaya, Yusuf Baran (2023) - Vaccines
5. Immunopharmacological Activities of Luteolin in Chronic Diseases.
   Lei Huang, Mi-Yeon Kim, Jae Youl Cho (2023) - International journal of molecular sciences
6. Luteolin as an anti-inflammatory and neuroprotective agent: A brief review.
   Seyed Fazel Nabavi, Nady Braidy, Olga Gortzi, Eduardo Sobarzo-Sanchez, Maria Daglia, Krystyna Skalicka-Woźniak, Seyed Mohammad Nabavi (2015) - Brain research bulletin
7. Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma.
   Duraisamy Kempuraj, Ramasamy Thangavel, Deepak D Kempuraj, Mohammad Ejaz Ahmed, Govindhasamy Pushpavathi Selvakumar, Sudhanshu P Raikwar, Smita A Zaheer, Shankar S Iyer, Raghav Govindarajan, Premkumar Nattanmai Chandrasekaran, Asgar Zaheer (2021) - BioFactors (Oxford, England)
8. Apigenin: A Therapeutic Agent for Treatment of Skin Inflammatory Diseases and Cancer.
   Ji Hye Yoon, Mi-Yeon Kim, Jae Youl Cho (2023) - International journal of molecular sciences
9. Luteolin, a flavone ingredient: Anticancer mechanisms, combined medication strategy, pharmacokinetics, clinical trials, and pharmaceutical researches.
   Mingyi Shi, Zixian Chen, Hui Gong, Zhaolei Peng, Qiang Sun, Kaipei Luo, Baoyu Wu, Chuanbiao Wen, Wei Lin (2024) - Phytotherapy research : PTR
10. From nature to therapy: Luteolin's potential as an immune system modulator in inflammatory disorders.
    Md Sadique Hussain, Gaurav Gupta, Ahsas Goyal, Riya Thapa, Waleed Hassan Almalki, Imran Kazmi, Sami I Alzarea, Shivkanya Fuloria, Dhanalekshmi Unnikrishnan Meenakshi, Vikas Jakhmola, Manisha Pandey, Sachin Kumar Singh, Kamal Dua (2023) - Journal of biochemical and molecular toxicology
11. Neuroprotective mechanisms of luteolin in glutamate-induced oxidative stress and autophagy-mediated neuronal cell death.
    Wudtipong Vongthip, Sunita Nilkhet, Kanokkan Boonruang, Monruedee Sukprasansap, Tewin Tencomnao, Seung Joon Baek (2024) - Scientific reports
12. Luteolin as a potential hepatoprotective drug: Molecular mechanisms and treatment strategies.
    Chenhao Yao, Shu Dai, Cheng Wang, Ke Fu, Rui Wu, Xingtao Zhao, Yuxin Yao, Yunxia Li (2023) - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
13. Luteolin suppresses androgen receptor-positive triple-negative breast cancer cell proliferation and metastasis by epigenetic regulation of MMP9 expression via the AKT/mTOR signaling pathway.
    Han-Tsang Wu, Joseph Lin, Yi-En Liu, Hsiao-Fan Chen, Kai-Wen Hsu, Shu-Hsuan Lin, Kai-Yen Peng, Kuo-Juei Lin, Chang-Chi Hsieh, Dar-Ren Chen (2021) - Phytomedicine : international journal of phytotherapy and phytopharmacology
14. Luteolin: Nature's promising warrior against Alzheimer's and Parkinson's disease.
    Ahsas Goyal, Kunal Solanki, Aanchal Verma (2024) - Journal of biochemical and molecular toxicology
15. Recent Updates on Source, Biosynthesis, and Therapeutic Potential of Natural Flavonoid Luteolin: A Review.
    Nandakumar Muruganathan, Anand Raj Dhanapal, Venkidasamy Baskar, Pandiyan Muthuramalingam, Dhivya Selvaraj, Husne Aara, Mohamed Zubair Shiek Abdullah, Iyyakkannu Sivanesan (2022) - Metabolites
16. Luteolin Mitigates D-Galactose-Induced Brain Ageing in Rats: SIRT1-Mediated Neuroprotection.
    Reham L Younis, Rehab M El-Gohary, Asmaa A Ghalwash, Islam Ibrahim Hegab, Maram M Ghabrial, Azza M Aboshanady, Raghad A Mostafa, Alaa H Abd El-Azeem, Eman E Farghal, Asmaa A E Belal, Haidy Khattab (2024) - Neurochemical research
17. Luteolin: a flavonoid with a multifaceted anticancer potential.
    Parteek Prasher, Mousmee Sharma, Sachin Kumar Singh, Monica Gulati, Dinesh Kumar Chellappan, Flavia Zacconi, Gabriele De Rubis, Gaurav Gupta, Javad Sharifi-Rad, William C Cho, Kamal Dua (2022) - Cancer cell international
18. Luteolin: exploring its therapeutic potential and molecular mechanisms in pulmonary diseases.
    Jialian Lv, Xinyue Song, Zixin Luo, Duoqin Huang, Li Xiao, Kang Zou (2025) - Frontiers in pharmacology
19. Novel extraction techniques and pharmaceutical activities of luteolin and its derivatives.
    Muhammad Faisal Manzoor, Nazir Ahmad, Zahoor Ahmed, Rabia Siddique, Xin-An Zeng, Abdul Rahaman, Rana Muhammad Aadil, Abdul Wahab (2019) - Journal of food biochemistry

This article summarizes published research for educational purposes. It is not medical advice. Talk to your doctor before starting, stopping, or changing any supplement or medication.